Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study we wish to test the hypothesis that continuous Gilenya treatment alters immune homeostasis in favor of an anti-inflammatory type II monocyte and macrophage (M2) phenotype in the circulation of patients with relapsing-remitting Multiple Sclerosis (MS). In this study we will determine the change in ratio of M2 (type II, alternatively activated) versus M1 (type I, classically activated) monocytes and macrophages in a cohort of patients that have received continuous Gilenya treatment for 0, 1, 3, 6 or 12 months. We will also assess changes in cell surface expression of the M1 marker CCR7 and the M2 markers CD206 or CD301 by monocytes and macrophages using FACS analysis of whole blood, and assess the tyrosine phosphorylation of the signal transducer and activator of transcription STAT-1 (pTyr-STAT1), which is critical for the activation of M1 myeloid cells. We will assess correlates with changes in M1 and M2 cytokine expression assessing possible mechanisms of action of Gilenya on myeloid lineage cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

NCT02137707

Multiple Sclerosis-Relapsing-Remitting

COMPLETED

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

NCT02021162

Multiple Sclerosis Healthy

COMPLETED

ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon

NCT01621269

Multiple Sclerosis

WITHDRAWN PHASE4

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

NCT01803867

Multiple Sclerosis

COMPLETED PHASE1

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

NCT02325440

Relapsing Remitting Multiple Sclerosis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gilenya treated - 1 month

Patient's taking continuous oral Gilenya at prescribed dose for 1 month.

Gilenya

Intervention Type DRUG

Gilenya treated - 3 months

Patient's taking continuous oral Gilenya at prescribed dose for 3 months.

Gilenya

Intervention Type DRUG

Gilenya treated - 6 months

Patient's taking continuous oral Gilenya at prescribed dose for 6 months.

Gilenya

Intervention Type DRUG

Gilenya treated - 12 months

Patient's taking continuous oral Gilenya at prescribed dose for 12 months.

Gilenya

Intervention Type DRUG

Gilenya qualified - untreated

Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gilenya

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must qualify to receive treatment with Gilenya, according to the University of Southern California, Department of Neurology, MS Group, Gilenya Prescribing Process.
* Clinically definite Multiple Sclerosis defined by the revised McDonald criteria (Polman et al., 2005, Polman et al., 2010) of the relapsing-remitting form with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5.
* Ability to understand and sign this study-specific institutional review board-approved informed consent form.
* Willing to donate \~50mls of blood for immunological testing on up to five occasions.

Exclusion Criteria

* Patient does not qualify to receive treatment with Gilenya, according to the USC, Department of Neurology, MS Group, Gilenya Prescribing Process.
* Inability to understand nature of the study.
* Treatment with any of the following within 30 days of commencing treatment with Gilenya: Avonex, Betaseron, Rebif, Copaxone, Natalizumab, Rituximab, Mitoxantrone, Cyclophosphamide, Cyclosporine, Azathioprine, Methotrexate or any other immunomodulatory, immunosuppressant or immune homeostasis altering drug.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No